Anti-msln antibodies and methods of use
AssigneesShanghai Henlius Biotech, Inc., Shanghai Henlius Biopharmaceutical Co., Ltd., Shanghai Henlius Biologics Co., Ltd.
InventorsPei-Hua LIN, Wei-Dong JIANG, Wenfeng XU, Hassan ISSAFRAS, Chi-Ling TSENG, Jiin-Tarng WANG
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to antibodies and antibody derivatives that bind to MSLN and methods of using the same. In certain embodiments, the antibody or antibody derivative disclosed herein comprises a single domain antibody that binds to MSLN.
Claims30
1-6. (canceled)
An antibody that binds to MSLN, comprising a single domain antibody comprising a heavy chain variable region comprising:
- a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 1, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 2, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 3,
- b) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 6, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 7, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 8,
- c) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 11, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 12, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 13,
- d) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 16, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 17, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 18,
- e) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 21, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 22, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 23,
- f) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 26, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 27, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 28,
- g) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 31, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 32, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 33, or
- h) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 36, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 37, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 38.
8-15. (canceled)
(canceled)
19-24. (canceled)
26-27. (canceled)
29-31. (canceled)
35-50. (canceled)
52-53. (canceled)
55-57. (canceled)
59-60. (canceled)
67-81. (canceled)
(canceled)
Dependencies are inferred from the claim text.